GlobeNewsWire
04 Feb 2026, 21:47 UTC · 31w ago
Verdict
Headline takes no side. We score TPST +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Tempest Therapeutics has extended its cash runway through mid-2027 via financing support from Factor Bioscience Inc.
So whatExtended liquidity is critical for clinical-stage biotech companies to avoid dilutive funding rounds and reach key clinical milestones.
More positive than 91% of claims this week
Tempest closed an all-stock acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 77% of claims this week
The company expects multiple significant clinical and regulatory milestones over the next 12-18 months.
So whatNear-term catalysts typically drive stock volatility and provide the market with valuation benchmarks.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company closed a strategic acquisition of CAR-T assets and secured financing, extending its cash runway and diversifying its pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
WSJ
12h ago
−68.3%
Price is moving against the score
$0.7554 vs $2.38 close before publication (Feb 4) · not market-adjusted
TPST chart →
